Growth of pancreatic cancers with hemizygous chromosomal 17p loss of MYBBP1A can be preferentially targeted by PARP inhibitors.
Hsieh A, Pitarresi JR, Lerner J, Donahue G, Hsiehchen D, Rustgi AK, Zaret K. Growth of pancreatic cancers with hemizygous chromosomal 17p loss of MYBBP1A can be preferentially targeted by PARP inhibitors. Sci Adv. 2020 12; 6(49).